The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented is solely approved for use in the US by the US Food and Drug Administration (FDA) in chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The compound is still being investigated for uses that have not been approved by the European Medicines Agency (EMA) and other health authorities.
European Association for the Study of DiabetesIndustry Symposium PresentationsSeptember 19–23, 2021
Recordings of the Presentations of the Bayer Industry Symposium at the European Association of the Study of Diabetes 58th Annual Meeting 2022
Thank you for your interest! Please see below to view the videos and to download the presentations from the Bayer Industry Symposia at the EASD Congress 2022.
Access to the slides will be available after their presentation at the congress.
Finerenone
Wednesday 21 September, 2022 | 18:45–19:45 CEST | On Demand
EASD 2022 Industry Symposium
Nonsteroidal MRAs in CKD and T2D: Current knowledge and practical insights
Session type: Industry SymposiumFaculty: Peter Rossing (chair), Janet McGill & Magnus Löndahl
View Video
Download the Slide Deck
Thursday 22 September, 2022 | 18:30–19:30 CEST | On Demand
EASD 2022 Industry Symposium
Nonsteroidal MRAs in patients with CKD and T2D: What is next for finerenone?
Session type: Industry SymposiumFaculty: Samy Hadjadj (chair), Hiddo Heerspink, Paola Fioretto & Christoph Wanner
View Video
Download the Slide Deck
MA-M_FIN-ALL-0921-2